Results 121 to 130 of about 1,144,970 (369)
Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles
Molecular Neurodegeneration, 2019 Alpha-synuclein (αS) is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).
Richard M. Meade, D. Fairlie, J. Mason
semanticscholar +1 more source
Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease
Scientific Reports, 2020 The objective of the study was to estimate if altered levels of alpha-synuclein can be detected in tear fluid of patients with Parkinson’s disease (PD).
F. Maass +10 more
semanticscholar +1 more source
Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein. [PDF]
, 2014 BackgroundSleep disruptions occur early and frequently in Parkinson's disease (PD). PD patients also show a slowing of resting state activity. Alpha-synuclein is causally linked to PD and accumulates in sleep-related brain regions.
Chesselet, Marie-Françoise +3 more
core
Transducer Materials Mediated Deep Brain Stimulation in Neurological Disorders
Advanced Functional Materials, EarlyView.This review discusses advanced transducer materials for improving deep brain stimulation (DBS) in neurological disorders. These materials respond to light, ultrasound, or magnetic fields, enabling precise, less invasive neuromodulation. Their stimulus‐responsive properties enhance neural control and adaptive therapy, paving the way for next‐generation ...
Di Zhao +5 more
wiley +1 more source
Frontiers in Neuroscience, 2019 Accumulation and aggregation of misfolded alpha-synuclein is believed to be a cause of Parkinson’s disease (PD). Phosphorylation of alpha-synuclein at S129 is known to be associated with the pathological misfolding process, but efforts to investigate the
Cristina Cariulo +15 more
doaj +1 more source
Frontiers in Aging Neuroscience, 2020 Parkinson’s disease (PD) is a debilitating neurodegenerative disorder defined by a loss of dopamine-producing neurons in the substantia nigra in the brain. It is associated with cytosolic inclusions known as Lewy bodies.
Sarah M. Hernandez +2 more
doaj +1 more source
Acta Neuropathologica Communications, 2020 It is necessary to develop an understanding of the specific mechanisms involved in alpha-synuclein aggregation and propagation to develop disease modifying therapies for age-related synucleinopathies, including Parkinson’s disease and Dementia with Lewy ...
Allison J Schaser +10 more
semanticscholar +1 more source
Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse [PDF]
, 2018 Alpha-synuclein is the main component of Lewy bodies, a histopathological finding of Parkinson's disease. Prolyl oligopeptidase (PREP) is a serine protease that binds to alpha-synuclein and accelerates its aggregation in vitro.
Julku, Ulrika H. +7 more
core +1 more source
Advanced Healthcare Materials, EarlyView.This work presents a low‐cost, reagent‐free point‐of‐care biosensor integrating redox‐active polyphenol red molecularly imprinted polymers (pPhR MIPs) on highly porous gold (HPG) electrodes for ultrasensitive detection of phosphorylated tau 181 (p‐Tau 181), an Alzheimer’s disease biomarker, in undiluted biofluids.
Sudhaunsh Deshpande +4 more
wiley +1 more source
F1000Research, 2014 The accumulation of misfolded a-synuclein is mechanistically linked to neurodegeneration in Parkinson’s disease (PD) and other alpha-synucleinopathies. However, how alpha-synuclein causes neurodegeneration is unresolved.
Yan Liu +5 more
doaj +1 more source